Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year’s analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.

造血细胞移植（HCT）广泛用于治疗获得性和先天性造血系统疾病。欧洲及相关国家进行的移植数量继续增加，2018 年，50 个国家的 701 个中心报告了 42,901 名患者 [19,630 例同种异体 (41%) 和 27,838 例自体 (59%)] 进行了 47,468 例 HCT。主要适应症是骨髓恶性肿瘤 10,679 ( 25%；97% 同种异体），淋巴恶性肿瘤 27,318 例（64%；20% 同种异体），实体瘤 1625 例（4%；2.9% 同种异体），非恶性疾病 3063 例（7%；81% 同种异体）。今年的分析重点是细胞疗法，CAR T 细胞疗法的患者人数显着增长，从 2017 年报告的 151 名患者增加到 2018 年报告的 301 名患者。其他细胞疗法的数量变化不大。 HCT 的重要趋势包括慢性期 CML 的同种异体 HCT 增加了 49%（尽管移植数量仍然很低），再生障碍性贫血增加了 24%。在自体 HCT 中，自身免疫性疾病持续增加（增加 19%），主要是由于多发性硬化症的活动。该年度报告反映了当前的活动并强调了对医疗保健规划有用的重要趋势。